Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 ICON, Intel Enter Pharma Analytics Platform Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News

ICON, Intel Enter Pharma Analytics Platform Pact

ICON to offer the Intel Pharma Analytics Platform for use in clinical trials

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ICON plc has entered an agreement with Intel Corp. to enable ICON to offer the Intel Pharma Analytics Platform for use in clinical trials. The Intel platform is an edge-to-cloud artificial intelligence (AI) solution that enables remote monitoring and continuous capture of clinical data from study subjects using sensors and wearable devices and can apply machine learning techniques to objectively measure symptoms and quantify the impact of therapies.

Jointly configured by ICON and building on Intel’s AI and analytics, the Intel Pharma Analytics Platform aims to allow pharmaceutical companies to increase speed, simplify clinical trials, and gather more objective evidence by transitioning to automatic collection of consistent, unbiased data, remote monitoring for data analysis, and delivering improved patient experience. These changes aim to help produce high-quality data and increase patient retention.

“Our engagement with Intel  confirms ICON’s position as the leading CRO for advancing the use of wearable technology, and will expand ICON’s existing offering to include a service where data can be aggregated and analyzed from mhealth and wearable technologies, with advanced analytics allowing for development of novel endpoints and digital biomarkers,” commented Steve Cutler, chief executive officer at ICON. “Furthermore, the platform supports patient centric trial designs by reducing or eliminating the need for patients to travel to sites and can be integrated with our Direct to Patient Call Centre (DPC) providing a seamless compliance monitoring service.”

“Intel is accelerating the pace of digital transformation, and IT plays a leading role in delivering solutions on that journey,” said Paula Tolliver, corporate vice president and chief information officer, Intel Corp.  “With the power of AI, the Intel Pharma Analytics Platform helps the clinical trial industry reduce costs and deliver fresh insights for drug development, potentially saving thousands of lives.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics